A new implant device to prevent edema-associated underdosage in high-dose-rate interstitial brachytherapy of mobile tongue cancer.
high-dose-rate interstitial brachytherapy
mobile tongue cancer
silicone device
tongue edema
Journal
Journal of contemporary brachytherapy
ISSN: 1689-832X
Titre abrégé: J Contemp Brachytherapy
Pays: Poland
ID NLM: 101506276
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
26
06
2019
accepted:
24
10
2019
entrez:
24
1
2020
pubmed:
24
1
2020
medline:
24
1
2020
Statut:
ppublish
Résumé
Tongue edema is a potential cause of treatment target underdosage in high-dose-rate interstitial brachytherapy (HDR-ISBT) of mobile tongue cancer. To prevent such edema-associated alteration of dosimetry, we developed a special silicon device. In this report we communicate our initial experience with two mobile tongue cancer patients whom we treated using this new device. The device consists of silicone tubes with a fixed width and scalable length depending on tongue size. These tubes are lined and fixed like a palisade, allowing the device to be used also as a template. The device is placed next to the lateral border of the tongue and on the floor of the mouth. In addition, a vinyl template can be placed on the dorsal tongue surface with both devices combined for implantation guidance. Between June and August 2012, two patients with locally confined tongue cancer were treated. Between June and August 2012, two mobile tongue cancer patients classified as cT2N0M0 were treated with HDR-ISBT using the silicone device. They underwent ISBT as monotherapy with fractional doses of 6.0 Gy up to a total physical dose of 54.0 Gy. The D The described silicone device has the potential to prevent underdosage to the treatment target related to tongue edema. It has been shown to be safe and easy to implement.
Identifiants
pubmed: 31969916
doi: 10.5114/jcb.2019.91225
pii: 39403
pmc: PMC6964338
doi:
Types de publication
Case Reports
Langues
eng
Pagination
573-578Informations de copyright
Copyright © 2019 Termedia.
Références
Strahlenther Onkol. 1992 Nov;168(11):617-21
pubmed: 1455289
Radiother Oncol. 2009 May;91(2):150-6
pubmed: 19329209
Rontgenpraxis. 2002;54(6):232-7
pubmed: 12174447
PLoS One. 2016 Apr 29;11(4):e0154226
pubmed: 27128434
J Contemp Brachytherapy. 2017 Feb;9(1):66-70
pubmed: 28344606
Brachytherapy. 2015 Jul-Aug;14(4):440-8
pubmed: 25858904
Australas Radiol. 2003 Jun;47(2):172-6
pubmed: 12780447
Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):1201-4
pubmed: 8985043
J Radiat Res. 2014 Jan 1;55(1):154-61
pubmed: 23732769
Brachytherapy. 2010 Jul-Sep;9(3):208-12
pubmed: 20149758
Strahlenther Onkol. 2004 Dec;180(12):768-75
pubmed: 15592696
Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1205-11
pubmed: 10725633
Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):61-9
pubmed: 11163498
J Contemp Brachytherapy. 2017 Dec;9(6):553-560
pubmed: 29441100
Cancer. 2009 Oct 1;115(19):4636-44
pubmed: 19569250
Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):171-5
pubmed: 11516867
Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1190-8
pubmed: 11483328
Radiother Oncol. 2017 Feb;122(2):248-254
pubmed: 27889184
J Contemp Brachytherapy. 2014 Mar;6(1):10-4
pubmed: 24790616